NCT03310957 2025-12-12Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerSeagen Inc.Phase 1/2 Completed185 enrolled 23 charts